Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy

被引：6
|
作者：
Kang, Seung Hyun [1 ]
Lee, Chang-Han [1 ,2 ,3 ,4 ]
机构：
[1] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 03080, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 03080, South Korea
[3] SNU, Wide River Inst Immunol WRII, Hongcheon 25159, South Korea
[4] Seoul Natl Univ, Coll Med, SNU Dementia Res Ctr, Seoul 03080, South Korea
来源：
BIOTECHNOLOGY AND BIOPROCESS ENGINEERING | 2021年 / 26卷 / 03期
关键词：
therapeutic antibody; antibody engineering; Fc engineering; bispecific antibody; FC-GAMMA RECEPTORS; MEMORY B-CELLS; MONOCLONAL-ANTIBODIES; IN-VIVO; ENGINEERED ANTIBODY; R-BINDING; HALF-LIFE; CLINICAL DEVELOPMENT; AFFINITY MATURATION; EFFECTOR FUNCTIONS;
D O I：
10.1007/s12257-020-0181-8
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Monoclonal antibodies (mAb) have been used as therapeutic agents for various diseases, and immunoglobulin G (IgG) is mainly used among antibody isotypes due to its structural and functional properties. So far, regardless of the purpose of the therapeutic antibody, wildtype IgG has been mainly used, but recently, the engineered antibodies with various strategies according to the role of the therapeutic antibody have been used to maximize the therapeutic efficacy. In this review paper, first, the overall structural features and functional characteristics of antibody IgG, second, the old and new techniques for antibody discovery, and finally, several antibody engineering strategies for maximizing therapeutic efficacy according to the role of a therapeutic antibody will be introduced.
引用
收藏
页码：295 / 311
页数：17
相关论文
共 50 条
  • [31] Therapeutic monoclonal antibodies in oncology
    Bouzid, K.
    Bedairia, N.
    Marty, M.
    PATHOLOGIE BIOLOGIE, 2012, 60 (04): : 223 - 228
  • [32] Pharmacokinetic variability of therapeutic antibodies
    Ternant, David
    Chhun, Stephanie
    M S-MEDECINE SCIENCES, 2020, 35 (12): : 1130 - 1136
  • [33] Safety of Therapeutic Monoclonal Antibodies
    Niebecker, Ronald
    Kloft, Charlotte
    CURRENT DRUG SAFETY, 2010, 5 (04) : 275 - 286
  • [34] Therapeutic use of monoclonal antibodies
    Garcia Ramos, S. E.
    Garcia Poza, P.
    Ramos Diaz, F.
    ARS PHARMACEUTICA, 2011, 52 (03) : 46 - 57
  • [35] Therapeutic antibodies for multiple myeloma
    Ishida, Tadao
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (11) : 957 - 963
  • [36] Effector functions of therapeutic antibodies
    Boross, Peter
    Peipp, Matthias
    Nimmerjahn, Falk
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [37] Infectious complications of the therapeutic antibodies
    Lebranchu, Y.
    REVUE DE MEDECINE INTERNE, 2015, 36 : A19 - A21
  • [38] Therapeutic monoclonal antibodies in ophthalmology
    Rodrigues, Eduardo B.
    Farah, Michel E.
    Maia, Mauricio
    Penha, Fernando M.
    Regatieri, Caio
    Melo, Gustavo B.
    Pinheiro, Marcelo M.
    Zanetti, Carlos R.
    PROGRESS IN RETINAL AND EYE RESEARCH, 2009, 28 (02) : 117 - 144
  • [39] Harnessing Fc receptor biology in the design of therapeutic antibodies
    Sondermann, Peter
    Szymkowski, David E.
    CURRENT OPINION IN IMMUNOLOGY, 2016, 40 : 78 - 87
  • [40] Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions
    Abdeldaim, Dalia T.
    Schindowski, Katharina
    PHARMACEUTICS, 2023, 15 (10)
12345